Education and training
Dr Alexandra Nanzer-Kelly undertook her specialist respiratory training in London, working across general and specialist respiratory and general medicine at St Mary’s and Chelsea and Westminster Hospitals, completing her specialist training here at Royal Brompton & Harefield NHS Foundation Trust.
Alongside her clinical training, she undertook research with the Medical Research Council (MRC) and Asthma UK’s Centre in Allergic Mechanisms of Asthma at King’s College London, in collaboration with the Blizard Institute at Barts and the London School of Medicine and Dentistry and supported by Asthma UK.
Her work focused on the immune regulation of severe, therapy refractory asthma and her thesis was presented for her PhD from the University of London. Her studies have contributed to our understanding of the immunology of severe asthma and she has published widely on this subject and also contributed to textbooks in these areas of clinical and scientific interest.
Dr Nanzer-Kelly has also received an award from the Edward Jenner programme by the NHS Leadership Academy.
Dr Nanzer-Kelly is a consultant respiratory physician at Royal Brompton Hospital and is trained in all areas of respiratory medicine. She specialises in the diagnosis and management of severe asthma and the complications of its treatment.
Her work provides patients with severe asthma a safe, efficient and patient centered service and is developing a novel clinical service in collaboration with the Trust’s metabolic specialists.
Through her specialist metabolic asthma clinic, with a team of physiotherapists and dieticians, patients referred and managed at the Royal Brompton are offered a unique, integrated, whole-system programme of treatment.
This programme focuses on:
- physical activity
- bone health
- psychological health.
There is also world-leading attention to the airways and breathing.
Dr Nanzer-Kelly has particular specialist interests in the adverse metabolic, skeletal and psychological effects of steroid therapy that many patients with severe asthma are dependent on and the management of asthma in the overweight patient.
She has unique training in this area, having spent part of her postgraduate training at the Department of Endocrinology at St Bartholomew’s Hospital, where she saw the deleterious effects of endogenous Cushing’s syndrome while studying the role of ghrelin on pituitary tumour development.
She has maintained and developed this interest in steroid therapy through her clinical training and her research into the immunology of steroid insensitive asthma.
Dr Nanzer-Kelly is a member of the Royal College of Physicians, the British Thoracic Society and the European Respiratory Society.
Dr Nanzer-Kelly lectures on the Imperial College London allergy MSc course. She is a clinical and educational supervisor to trainees at the Royal Brompton and has examined for Barts and the London School of Medicine objective structured clinical examination (OSCE) examinations.
Chambers ES, Nanzer AM, Corrigan C, Hawrylowizc CM et al 'Distinct endotypes of steroid resistant asthma characterized by IL-7A and IFNg immunophenotypes' Journal of Allergy and Clinical Immunology 2015 Sep;136(3):628-637.e4
Nanzer AM, Chambers ES, Corrigan C, Hawrylowizc CM et al 'The effects of calcitriol treatment in glucocortico-resistant asthma' Journal of Allergy and Clinical Immunology 2014 Jun;133(6):1755-7.e4
Nanzer AM, Jordan S, Paddley Set al 'A deadly web. Case Report' Thorax. 2015 Jan;70(1):101
Nanzer AM, Menzies-Gow A 'Steps to better understand severe asthma' The Prescriber 2015
Nanzer AM, Menzies-Gow A 'Defining severe asthma – an approach to find new therapies' Eur Clin Respir J. 2014 Jun 5;1. doi: 10.3402/ecrj.v1.24356. eCollection 2014. Review
Nanzer AM, Menzies-Gow A 'Quick Guide on Severe Asthma' Pulse Learning review 2014
Nanzer AM, Janssen J, Hind M 'Sniffing out a hidden cause of breathlessness.' Case Report BMJ Case Rep. 2014 Jun 27;2014. pii: bcr2014204996
Nanzer AM, Chambers ES, Corrigan C, Hawrylowizc CM et al 'Enhanced production of IL-17A in patients with severe asthma is inhibited by 1a,25- dihydroxyvitamin D3 in a glucocortico-independent fashion' Journal of Allergy and Clinical Immunology 2013 Aug;132(2):297-304.e3
Nanzer AM, Chambers ES,Corrigan C, Hawrylowizc CM et al 'Serum 25-dihydroxyvitamin D levels correlate with CD4(+)FoxP(+) T-cell numbers in moderate and severe asthma' Journal of Allergy and Clinical Immunology 2012 Aug;130(2):542-4
Nanzer AM, Dimeloe S, Ryanna K, Hawrylowicz C 'Regulatory T cells, inflammation and the allergic response. The role of glucocorticoids and Vitamin D' Journal of Steroid Biochemistry and Molecular Biology 2010 May 31;120(2-3):86-95. Review
Martineau AR, Nanzer AM, Satkunam KR, et al 'Influence of a single oral dose of vitamin D(2) on serum 25-hydroxyvitamin D concentratons in tuberculous patients' International Journal Tuberculosis and Lung Disease 2009 Jan;13(1):119-25
Hubina E, Nanzer AM, Hanson MR, et al
'Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours' European Journal of Endocrinology 2006 Aug;155(2):371-9
Emery MN, Lentiou C, Bonner SE, Merulli C, Nanzer AM, et al 'PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor' Clinical Endocrinology (oxf). 2006 Sep;65(3):389-95
Hubina E, Ruscica M, Nanzer AM, Korbonits M et al 'Novel molecular aspects of pituitary tumours' Journal of Endocrinological Investigation 2005;28(11 Suppl International):87-92
Musat M, Korbonits M, Kola B, Hanson MR, Nanzer AM, Grossman AB et al' Enhanced protein kinase B/Akt signalling in pituitary tumours' Endocrine Related Cancer. 2005 Jun;12(2):423-33
Nanzer AM, Khalaf S, Grossman AB et al 'Ghrelin exerts a proliferative effect on a rat pituitary somatotroph cell line via the mitogen-activated protein kinase pathway' European Journal of Endocrinology. 2004 Aug;151(2):233-40
Korbonits M, Morris D, Nanzer AM, Grossman AB et al 'Role of regulatory factors in pituitary tumour formation' Frontiers of Hormone Research. 2004;32:63-95. Review
Morgan M, Nanzer AM, Cecilia Camacho-Hubner, et al
'Hypoglycaemia secondary to the secretion of pro-insulin like growth factor II by a metastatic neuroendocrine tumour with sarcomatous differentiation.' Hormones (Athens). 2003 Apr-Jun;2(2):125-9.